drugset / Trial / NCT02901548
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
Phase 2
Terminated
17 enrolled
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test if an experimental drug called Durvalumab (Medi4736) given by intravenous (IV) infusion is effective in treating carcinoma in situ (CIS) of the bladder that no longer responds to Bacillus Calmette-Guérin (BCG) and to collect information on the safety of these drugs and whether they cause any side effects.
Timeline
- Start
- 2017-02-16
- Primary completion
- 2020-07-24
- Completion
- 2021-09-07
Outcome
Outcome not reported
Stopped: “Study closed early due to futility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 1500 mg/kg | Intravenous |